News and commentary from the world of neurology and neuroscience
Triptans are efficacious and underused, researchers say
Investigational Lu AG09222 met primary end point in proof-of-concept trial
But not everyone can reliably identify prodrome events, notes expert
At 48 weeks, atogepant showed consistent safety profile and efficacy
Findings may point to novel biomarker